No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

6/1

Eli Lilly

Hanmi

Pharmaceutical

Sonefpeglutide

GLP-2R agonist

Gastrointestinal

Short bowel syndrome

Phase 2

1,260

2

6/1

Eli Lilly

Haisco

Pharmaceutical

-

5 small molecule discovery

programs

n/d

n/d

Discovery

3,054

3

6/1

Agios

Pharmaceuticals

Oscotec

Cevidoplenib

SYK inhibitor

Immunology

Immune

thrombocytopenia

Phase 2

665

4

6/2

Travere

Therapeutics

Everest Medicines

Civorebrutinib

BTK inhibitor

Immunology

Primary membranous

nephropathy

Phase 1/2

1,142.5

5

6/3

Eli Lilly

Ascidian

Therapeutics

n/d

RNA exon-editing platform

Genitourinary

Genetic kidney disease

Discovery

1,900

6

6/4

Alnylam

Inceptive

-

AI-driven oligonucleotide design

for RNAi therapeutics

-

-

Discovery

2,000

7

6/4

Stipple Bio

Lonza

‘GlycoConnect®’

A platform for site-specific

payload conjugation via native

antibody glycan remodeling

Oncology

Cancer

Preclinical

n/d

8

6/8

Roche

Nurix Therapeutics

Bexobrutideg

BTK degrader

Oncology

CLL

B-cell malignancies

Phase 3

Phase 1

2,300

9

6/8

GSK

Engitix

-

Human ECM platform with multi-

omics–driven target discovery

Metabolic

disorder

Liver fibrosis regression

Discovery

217.2

10

6/9

Cartesian

Therapeutics

WestGene

Biopharma

n/d

tLNP platform for transient

CAR/TCE expression

Immunology

Myasthenia gravis

Phase 1

n/d

11

6/9

Eli Lilly

AlzeCure Pharma

ACD680

Selective Aβ42 lowering

γ-secretase modulator

Neurology

Alzheimer’s disease

Preclinical

1,000

12

6/10

Novartis

Orionis

‘Allo-glue’

Small-molecule induced protein

interaction platform

-

-

Discovery

1,440

13

6/16

Everest

Dimerix

DMX-200

CCR2 antagonist

Genitourinary

Focal Segmental

Glomerulosclerosis

Phase 3

340

14

6/16

MultiValent

Biotherapies*

Coherent

Biopharma

MVB-101
(CBP-1018)

PSMA x FRα PDC

Oncology

Prostate cancer

Precliical

n/d

15

6/17

Jazz

Pharmaceuticals

AbCellera

n/d

CD3-binding TCE platform

Oncology

Gastrointestinal ​cancer,

Solid tumor

Discovery

876

16

6/18

cAMPfield

Newsoara

Prifemilast

PDE-4 inhibitor

Immunology

Ulcerative colitis,

Crohn’s disease

Phase 2

180+

17

6/18

Memento

medicines*

MabTics,
Curacle

MMT-205(MT103)

Tie2 x VEGF BsAbs

Ophthalmology

nAMD, DME

Preclinical

1,078

18

6/18

Voro

Therapeutics

Alloy Therapeutics

n/d

A masked TCE discovery platform

 combining Voro’s tumor-

activation technology with

Alloy’s CD3 antibody platform

Oncology

Cancer

Discovery

n/d

19

6/22

Eli Lilly

BioArctic AB

BrainTransporterTM

BBB-crossing CNS delivery

platform

Neurology

Neurodegeneration

Discovery

800

20

6/22

Bionyra Pharma*

NovaRock

BYN-001(NBL-023)

αIL-25 mAb w/ half-life extension

 technology

Immunology

Atopic dermatitis

Preclinical

n/d

21

6/22

Bionyra Pharma*

TrueLab

Biopharmaceutical

BYN-002(TL-001)

BYN-003(TL-003)

αTL1A mAb

TL1A x IL-23p19 BsAbs

Immunology

Immunology

IBD

Ulcerative colitis

Phase 1

Phase 1

985

22

6/22

Nuvectis Pharma

Haisco

Pharmaceutical

NXP100

NXP200

CFB inhibitor

BRAF paradoxical breaker

inhibitor

Hematology

Oncology

PNH

Brain tumor

Registration

Phase 1

1,461

23

6/23

Serapha Bio*

YolTech

Therapeutics

SERP-01
(YOLT-202)

LNP-mediated in vivo gene

editing

Metabolic

disorder

Alpha-1-antitrypsin

deficiency

Phase 1

n/d

24

6/23

Eli Lilly

Sangamo

therapeutics**

‘STAC-BBB’

‘Zinc finger’

‘MINT’

ST-506

AAV capsid delivery platform

Zinc finger epigenetic regulator

platform for gene modulation

Modular integrase gene

engineering platform

AAV gene therapy

-

-

-

Neurology

-

-

-

Prion disease

-

-

-

Preclinical

50

25

6/23

Astellas

Sangamo

therapeutics**

Isaralgagene

civaparvovec

(ST-920)

Recombinant AAV2/6 vector

delivering alpha galactosidase A

Metabolic

disorder

Fabry disease

Phase 1/2

50

26

6/24

Boehringer

Ingelheim

Combotope

Therapeutics

‘SMART-Phase
discovery’

Glycan-protein target antibody

discovery platform

Oncology

Cancer

Discovery

n/d

27

6/24

Novartis

Antares

Therapeutics

n/d

Covalent small-molecule

discovery platform

Oncology

Cancer

Discovery

1,905

28

6/24

Eli Lilly

Abbisko

Therapeutics

n/d

n/d

n/d

n/d

Discovery

1,900

29

6/25

Recordati

Ionis

Pharmaceuticals

Zilganersen

ASO targeting GFAP mRNA

Neurology

Alexander disease

Registration

30+

30

6/26

Nippon Shinyaku

Elixirgen

EXG-7001

mRNA-mediated dystrophin

replacement

Musculoskeletal

Duchenne

Muscular dystrophy

Preclinical

n/d

31

6/30

Boulevard Bio

Metis TechBio

MTS-128

Trispecific TCE

Immunology

Autoimmune disease

Preclinical

1,620

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

6/1

Servier

Edgewise Therapeutics’ muscular dystrophy business

Sevasemten

Myosin inhibitor

Musculoskeletal

Becker muscular dystrophy
Duchenne muscular dystrophy

Phase 3

Phase 2

2,650

2

6/8

Incyte

Vega Therapeutics

VGA039

αPROS1 mAb

Hematology

Von willebrand disease

Phase 3

2,000

3

6/8

J&J

Firefly Bio

‘Firelink’

A DAC platform with catalytic

protein degrader payloads

Oncology

KRAS-mutant solid tumors

Preclinical

1,000

4

6/9

GSK

Nuvalent

Zidesamtinib

Neladalkib

NVL-330

ROS1 inhibitor

ALK inhibitor

HER2 inhibitor

Oncology

Oncology

Oncology

NSCLC

NSCLC

HER2-altered NSCLC

Registration

Registration

Phase 1

10,600

5

6/11

Adial

Pharmaceuticals

Azora Therapeutics

AT177

AhR agonist

Immunology

Ulcerative colitis

IND

32+

6

6/16

Eli Lilly

4E

4ET1103

MNK inhibitor

Neurology

Chronic pain

Phase 1

n/d

7

6/17

Biogen

RayThera

n/d

3 small-molecule

anti-inflammatory programs

Immunology

Immunological diseases

Preclinical

1,000

8

6/22

AbbVie

Apogee Therapeutics

Zumilokibart

αIL-13 mAb

Immunology

Atopic dermatitis, Eczema

Phase 2

10,900

9

6/29

Zymeworks

Theravance Biopharma

Yupelri

Ampreloxetine

Muscarinic antagonist

Norepinephrine transporter

Immunology

Cardiovascular disease

COPD

Neurogenic orthostatic

hypotension

Marketed

Phase 2

929

10

6/29

Ipsen

Kartos Therapeutics

Navtemadlin

MDM2 inhibitor

Oncology

Myelofibrosis

Phase 3

1,750